TY - JOUR
T1 - Propofol for gastrointestinal endoscopy
AU - Nishizawa, Toshihiro
AU - Suzuki, Hidekazu
N1 - Funding Information:
Over the last 2 years, H.S. received scholarship funds for research from Daiichisankyo Co Ltd, Otsuka Pharmaceutical Co Ltd and Tsumura Co Ltd, and received service honoraria from Astellas Pharm Inc, Astra-Zeneca K.K., EA Pharma Co Ltd, Mylan EPD Ltd, Otsuka Pharmaceutical Co Ltd, Takeda Pharmaceutical Co Ltd, Tsumura Co and Zeria Pharmaceutical Co Ltd. These sources of funding had no role in the design, practice or analysis of this study. There are no other conflicts of interest related to this article.
Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (B) (16H05291 to H.S.) and MEXT-Supported Program for the Strategic Research Foundation at Private Universities (S1411003, to H.S.).
Funding Information:
This work was supported by a Grant-in-Aid for Scientific Research (B) (16H05291 to H.S.) and Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Supported Program for the Strategic Research Foundation at Private Universities (S1411003, to H.S.).
Publisher Copyright:
© 2018, Author(s) 2018.
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Most gastrointestinal endoscopic procedures are now performed with sedation. Moderate sedation using benzodiazepines and opioids continues to be widely used, but propofol sedation is becoming more popular because its unique pharmacokinetic properties make endoscopy almost painless, with a very predictable and rapid recovery process. There is controversy as to whether propofol should be administered only by anesthesia professionals. According to published values, endoscopist-directed propofol has a lower mortality rate than endoscopist-delivered benzodiazepines and opioids, and a comparable rate to general anesthesia by anesthesiologists. Rapid recovery has a major impact on patient satisfaction, post-procedure education and the general flow of the endoscopy unit. According to estimates, the absolute economic benefit of endoscopist-directed propofol implementation in a screening setting is probably substantial, with 10-year savings of $3.2 billion in the USA. Guidelines concerning the use of propofol emphasize the need for adequate training and certification in sedation by non-anesthetists.
AB - Most gastrointestinal endoscopic procedures are now performed with sedation. Moderate sedation using benzodiazepines and opioids continues to be widely used, but propofol sedation is becoming more popular because its unique pharmacokinetic properties make endoscopy almost painless, with a very predictable and rapid recovery process. There is controversy as to whether propofol should be administered only by anesthesia professionals. According to published values, endoscopist-directed propofol has a lower mortality rate than endoscopist-delivered benzodiazepines and opioids, and a comparable rate to general anesthesia by anesthesiologists. Rapid recovery has a major impact on patient satisfaction, post-procedure education and the general flow of the endoscopy unit. According to estimates, the absolute economic benefit of endoscopist-directed propofol implementation in a screening setting is probably substantial, with 10-year savings of $3.2 billion in the USA. Guidelines concerning the use of propofol emphasize the need for adequate training and certification in sedation by non-anesthetists.
KW - Propofol
KW - gastrointestinal endoscopy
KW - sedative agents
UR - http://www.scopus.com/inward/record.url?scp=85044570574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044570574&partnerID=8YFLogxK
U2 - 10.1177/2050640618767594
DO - 10.1177/2050640618767594
M3 - Review article
AN - SCOPUS:85044570574
SN - 2050-6406
VL - 6
SP - 801
EP - 805
JO - United European Gastroenterology Journal
JF - United European Gastroenterology Journal
IS - 6
ER -